

Zhuyong Mei

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11750530/zhuyong-mei-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24
papers

4,826
citations

19
h-index

24
g-index

24
ext. papers

5,537
ext. citations

7
avg, IF

4.41
L-index

#	Paper	IF	Citations
24	CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL). <i>Blood</i> , 2018 , 132, 680-680	2.2	16
23	In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. <i>Molecular Therapy</i> , 2018 , 26, 2727-2737	11.7	107
22	CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. <i>Molecular Therapy</i> , 2017 , 25, 2214-2224	11.7	249
21	Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. <i>Cytotherapy</i> , 2017 , 19, 1225-1232	4.8	86
20	T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC. <i>Molecular Therapy - Oncolytics</i> , 2017 , 6, 69-79	6.4	15
19	Mesenchymal stromal cell secretomes are modulated by suspension time, delivery vehicle, passage through catheter, and exposure to adjuvants. <i>Cytotherapy</i> , 2017 , 19, 36-46	4.8	10
18	Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirceted lymphocytes. <i>Journal of Clinical Investigation</i> , 2017 , 127, 3462-3471	15.9	215
17	Clinical responses with T lymphocytes targeting malignancy-associated light chains. <i>Journal of Clinical Investigation</i> , 2016 , 126, 2588-96	15.9	207
16	Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1688-96	2.2	607
15	Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. <i>Cytotherapy</i> , 2014 , 16, 1048-58	4.8	98
14	Manufacturing mesenchymal stromal cells for phase I clinical trials. <i>Cytotherapy</i> , 2013 , 15, 416-22	4.8	48
13	Infusion of donor-derived CD19-redirceted virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. <i>Blood</i> , 2013 , 122, 2965-73	2.2	390
12	Clinical-Scale Expansion of Human Bone Marrow-Derived Mesenchymal Stromal Cells to Treat Patients After Ischemic Stroke.. <i>Blood</i> , 2012 , 120, 3021-3021	2.2	
11	Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. <i>Blood</i> , 2011 , 118, 6050-6	2.2	813
10	CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. <i>Journal of Clinical Investigation</i> , 2011 , 121, 1822-6	15.9	709
9	The Effects of Co-Stimulatory Endodomains on the Fate of T Cells Expressing a Tumor Directed Chimeric Antigen Receptor (CAR) In Human Subjects with B Cell Malignancies. <i>Blood</i> , 2010 , 116, 3949-3949	2.2	23
8	Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. <i>Nature Medicine</i> , 2008 , 14, 1264-70	50.5	919

7	A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. <i>Journal of Immunotherapy</i> , 2008 , 31, 812-9	5	31
6	Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. <i>Journal of Immunotherapy</i> , 2007 , 30, 227-33	5	41
5	Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. <i>Blood</i> , 2006 , 107, 1332-41	2.2	59
4	Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. <i>Blood</i> , 2003 , 101, 1718-26	2.2	105
3	Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 273-81	4.7	20
2	Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. <i>Cancer Gene Therapy</i> , 2001 , 8, 378-87	5.4	27
1	Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. <i>Human Gene Therapy</i> , 2001 , 12, 659-70	4.8	54